Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. develops induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. Its platform uses an iPSC cell foundry and Allo-Evasion™ immune-evasion engineering to create allogeneic beta islet, T cell and natural killer cell programs, including CNTY-813 for type 1 diabetes and CD19-targeted CAR-iT work such as CNTY-308.
Recurring company updates address preclinical data presentations, regulatory-pathway disclosures, financial results, investor presentations, board and committee changes, and collaboration economics tied to the company’s collaboration, option and license agreement with Bristol-Myers Squibb.
Century Therapeutics (NASDAQ: IPSC) reported first quarter 2026 results and pipeline progress. Cash, cash equivalents and marketable securities were $217.0 million on March 31, 2026, with a projected cash runway into Q1 2029. Net loss was $21.6 million.
CNTY‑813 remains on track for an IND in 4Q 2026 with initial clinical data expected in 2H 2027, while CNTY‑308 is expected to enter clinical testing in 2026. The company also completed a $135 million private placement in January 2026 and reduced R&D and G&A expenses year over year.
Century Therapeutics (NASDAQ: IPSC) will deliver an oral presentation at the American Diabetes Association 86th Scientific Sessions on June 8, 2026, highlighting CNTY-813, an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for type 1 diabetes.
The company says CNTY-813 is on track for an IND submission in 4Q 2026. Presentation details: oral talk by Leonardo Velazco-Cruz, PhD, abstract/session number 1318-OR, 2:45–3:00 p.m. CT.
Century Therapeutics (NASDAQ: IPSC) reported full-year 2025 results and pipeline progress on March 12, 2026. Key news: CNTY-813 is in IND-enabling studies with an IND submission expected in 4Q 2026 and initial clinical data anticipated in 2H 2027. CNTY-308 is advancing toward clinical entry in 2026. The company completed an oversubscribed $135 million private placement and says cash runway is extended into 1Q 2029. 2025 financials: cash and investments of $117.1 million, collaboration revenue of $109.2 million, R&D $95.7 million, G&A $24.0 million, and net loss of $9.6 million.
Century Therapeutics (NASDAQ: IPSC) will participate in two investor conferences in March 2026 with scheduled fireside chats: TD Cowen on March 4, 2026 at 9:50 a.m. ET in Boston and Leerink Partners on March 10, 2026 at 4:20 p.m. ET in Miami.
A live webcast will be available on Century's Investors page and archived replays will remain available for at least 30 days.
Century Therapeutics (NASDAQ: IPSC) secured an oversubscribed private placement expected to raise approximately $135 million in initial gross proceeds, led by TCGX with participation from RA Capital, Commodore Capital, Deep Track Capital, RTW, Venrock Healthcare Capital Partners and the T1D Fund.
The financing will issue ~117.39 million common shares (or pre-funded warrants) and warrants to purchase ~58.70 million shares at a purchase price of $1.15 per share, with accompanying warrants exercisable at $2.60. Full warrant exercise would provide an additional ~$153 million.
Century expects the offering to close on Jan 9, 2026, estimates the proceeds extend cash runway to Q1 2029, anticipates an IND submission in 2026 for CNTY-813 and initial clinical data in 2027. Proceeds are for development of CNTY-813 and general corporate purposes.
Century Therapeutics (NASDAQ: IPSC) appointed Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its Board of Directors effective December 9, 2025.
Dr. Lee will join the Audit and Compensation Committees; Dr. Murphy will join the Compensation and Nominating and Corporate Governance Committees. The company said the appointments support execution of its iPSC-derived cell therapy programs, including CNTY-813 for type 1 diabetes, and add capital-formation, corporate development and life-science investment experience to the board.
Century Therapeutics (NASDAQ: IPSC) will participate in the Piper Sandler 37th Annual Healthcare Conference in New York.
Events: Chad Cowan, Ph.D., will join the “State of the Art in Cell Therapy” panel at 12:00 p.m. ET on Tuesday, December 2, 2025. Brent Pfeiffenberger, Pharm.D., and Dr. Cowan will take part in a webcasted fireside chat at 10:00 a.m. ET on Wednesday, December 3, 2025. A live webcast will be available on Century’s Investors page at www.centurytx.com, with an archived replay available for at least 30 days.
Century Therapeutics (NASDAQ: IPSC) reported Q3 2025 results and a program update on Nov 13, 2025. The company announced a lead iPSC-derived beta islet program for Type 1 diabetes, CNTY-813, with IND-enabling studies planned to start by year-end 2025 and an IND submission targeted in 2026. CNTY-308 is advancing through IND-enabling studies with clinical entry expected in 2026. Century expects initial investigator-sponsored data for CNTY-101 from the CARAMEL IST on Dec 5, 2025 and will discontinue its company-sponsored CALiPSO-1 trial after five treated patients. As of Sept 30, 2025, cash and marketable securities were $132.7M, with an estimated runway into 4Q 2027. Q3 net loss was $34.4M.
Century Therapeutics (NASDAQ: IPSC) announced CNTY-813, an iPSC-derived beta islet program for Type 1 diabetes using its Allo-Evasion™ 5.0 immune-evasion platform to reduce T cell, NK cell and humoral rejection.
Company-reported preclinical results show rapid, sustained normalization of glucose in STZ diabetic models, detectable human C‑peptide, mature glucose‑stimulated insulin secretion (GSIS), and engineered resistance to NK‑ and antibody-mediated killing. Century says its suspension bioreactor process supports scalable manufacturing.
Regulatory timeline: IND‑enabling studies on track to start by year‑end 2025 with an IND submission planned as early as 2026.
Century Therapeutics (NASDAQ: IPSC) announced that Chad Cowan, Ph.D., Chief Scientific Officer, will present at Chardan’s 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025 at 12:20 p.m. ET in New York.
A live webcast of the presentation will be available on Century’s Investors page at www.centurytx.com, and an archived replay will be accessible for at least 30 days after the event.